Eric Santos, MD
Hematology & Oncology · Grand Rapids, MINPI 1174700256
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by AstraZeneca at 34.6% of the total. Reporting peaked in 2019 at $6,264 and has fallen 91.0% since, to $566 in 2025.
Across 127 payments — averaging $89.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Sanofi$3K
- Astrazeneca UK Limited$2K
- Foundation Medicine, Inc.$470
- E.r. Squibb & Sons, L.L.C.$463
- Array Biopharma Inc$238
- plus $2K from 27 others
Across 63 payments — averaging $24,078 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$868K
- AstraZeneca$258K
- Genentech, Inc.$151K
- Eli Lilly$114K
- Sanofi US Services Inc.$90K
- Merck$33K
- plus $2K from 1 others
What the payments were for
- Consulting fees$5,47348%
- Travel & lodging$2,52122%
- Food & beverage$3,38430%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 19 | $3,939 |
| Sanofi | 4 | $3,211 |
| Astrazeneca UK Limited | 9 | $1,559 |
| Foundation Medicine, Inc. | 3 | $470 |
| E.r. Squibb & Sons, L.L.C. | 10 | $463 |
| Array Biopharma Inc | 12 | $238 |
| Novartis | 13 | $217 |
| Gilead(2 entities) | 4 | $168 |
| Merck | 6 | $129 |
| Regeneron Healthcare Solutions, Inc. | 3 | $116 |
| Genentech USA, Inc. | 6 | $108 |
| Catalyst Orthoscience | 1 | $104 |
| Pfizer | 6 | $83 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $64 |
| Eli Lilly | 1 | $58 |
| Amgen | 3 | $55 |
| Eisai Inc. | 2 | $48 |
| Ipsen Biopharmaceuticals, Inc | 2 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Bristol Myers Squibb | 2 | $32 |
| GSK | 2 | $32 |
| Bayer | 2 | $27 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Mirati Therapeutics, Inc. | 1 | $20 |
| EUSA Pharma (US) LLC | 1 | $18 |
| Incyte Corporation | 1 | $17 |
| Seagen Inc. | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Mylan Institutional Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $13 |
| AbbVie | 1 | $13 |
| Puma Biotechnology, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$3,492
- LIBTAYO$1,481
- FOUNDATIONONE CDX$470
- FOUNDATIONONE$241
- FOUNDATIONONE HEME$241
- FOUNDATIONFOCUS$241
- FOUNDATIONONE LIQUID$241
- Epclusa$113
- Catalyst Total CSR$104
How this compares
$11,390 in reported general payments places this provider in the 85th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 79 | $1,291,936 |
| MekinistTrametinib Dimethyl Sulfoxide | 22 | $327,450 |
| TabrectaCapmatinib Hydrochloride | 12 | $275,448 |
| TafinlarDabrafenib Mesylate | 21 | $268,844 |
| GilotrifAfatinib Dimaleate | 18 | $197,261 |
| NeulastaPegfilgrastim | 15 | $100,718 |
| NyvepriaPegfilgrastim-Apgf | 11 | $40,428 |
| XareltoRivaroxaban | 46 | $32,547 |
| EliquisApixaban | 29 | $18,169 |
| Erlotinib Hcl | 11 | $4,004 |
| Prochlorperazine Maleate | 112 | $1,461 |
| Dexamethasone | 38 | $543 |
| Lidocaine Hcl ViscousLidocaine Hcl | 20 | $343 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 26 | $335 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 27 | $273 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $3,939 | $1,291,93679 claims |
| NovartisMekinist, Tabrecta, Tafinlar | $217 | $871,74255 claims |
| AmgenNeulasta | $55 | $100,71815 claims |
| PfizerNyvepria, Eliquis | $83 | $58,59640 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 282 hematology & oncology providers in Michigan.
Other hematology & oncology in Grand Rapids
- Sreenivasa ChandanaGrand Rapids$305K
- Nehal LakhaniGrand Rapids$13K
- Erin PettijohnGrand Rapids$10K
- Colin HardinGrand Rapids$10K
- Faisal MusaDearborn$976K
- Mohammed Al HallakDetroit$644K
- Daniel LebovicGrosse Pointe Woods$352K
- Mohammad ChistiTroy$180K
- Gordon SrkalovicLansing$167K
- Jeffrey ZonderDetroit$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.